UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/083,682	10/24/2001	Alan P. Wolffe	8325-0015.20	1541	
20855 ROBINS & PA	7590 03/08/201 STERNAK	EXAMINER			
	1731 EMBARCADERO ROAD			ZHOU, SHUBO	
SUITE 230 PALO ALTO, 0	CA 94303		ART UNIT	PAPER NUMBER	
			1631		
			MAIL DATE	DELIVERY MODE	
			03/08/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/083,682	WOLFFE ET AL.	
Examiner	Art Unit	
SHUBO (Joe) ZHOU	1631	

The MAILING DATE of this communication appears on the cover sheet with the correspondence	address
THE REPLY FILED <u>08 February 2010</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.3 for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the filed periods:	ce, which places the 31; or (3) a Request
a) The period for reply expiresmonths from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rej Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WA MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the approhave been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The apprunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	ejection. AS FILED WITHIN TWO opriate extension fee oropriate extension fee oropriate extension fee oropriate extension fee oropriate extension; or (2) as
NOTICE OF APPEAL	
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two model filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal converge of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS	
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying	
appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendments	ont (DTOL 324)
_	ent (PTOL-324).
 5.	dment canceling the
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and a how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:	an explanation of
AFFIDAVIT OR OTHER EVIDENCE	
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence was not earlier presented. See 37 CFR 1.116(e).	
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a bri entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(nt fails to provide a
10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or att REQUEST FOR RECONSIDERATION/OTHER	tached.
11. The request for reconsideration has been considered but does NOT place the application in condition for allo see continuation sheet.	wance because:
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s) 13. ☐ Other:	
/SHUBO (Joe) ZHOU/	
Primary Examiner, Art Unit 1631	

Continuation Sheet (PTO-303)

Application No.

Continuation of 7(b) and 11:

There appears to be no amendment made to the claims in the response filed 2/8/10.

The rejection of the claims under 35 USC 103(a) stands for the reasons set forth in the final rejection mailed 12/8/09, and applicant's arguments filed 2/8/10 have been fully considered but found unpersuasive.

It appears that applicant's arguments are on the ground that the cloning in Grosveld involves cloning a single sequence (i.e. "the target sequence") and a collection of the same polynucleotide molecules is not a library. This is not found persuasive. Firstly, in a reasonably broad sense, a collection of the same polynucleotide molecules is also a library, which meets the definition of the term defined in the instant specification as "a population of DNA fragments that have been propagated in some type of a cloning vector." See paragraph [0198] of the published application. This is akin to a collection of 100 the same books in a room for people to read. This collection of books is still a library albeit maybe a small and limited library, but it is still a library in the reasonably broad sense. Secondly, as set forth in the previous Office action such as on page 6 of the final rejection mailed 12/8/09, one of ordinary skill in the art would have been motivated to modify the method of Clontech and motivated by Grosveld et al. to treat the chromatin with the method of Grosveld et al. and not only clone the DNase I hypersensitive fragment from a readily made clone containing such fragment if the clone is available, but also to clone the Dnase I hypersensitive fragments directly from the fragments identified in column 8 if there are no clones readily available comprising such fragments in order to obtain such fragments which contain regulatory sequences because Grosveld et al. claim and suggest obtaining such fragments. A collection of clones containing these different fragments (which are DNase I hypersensitive, and hence the accessible regions) would also be a library.